Breaking News, Collaborations & Alliances

Nona, GeneQuantum Partner on Next-Gen Bioconjugates

Aims to further enhance technology platform capabilities providing services for the early discovery of next-generation bioconjugates.

Nona Biosciences, a company involved in technology innovation and antibody discovery and development services, entered into a strategic collaboration with GeneQuantum Healthcare to advance the early discovery of next generation bioconjugates. Nona Biosciences will integrate GeneQuantum’s iLDC (intelligent Ligase-dependent Conjugation) and iGDC (intelligent Glycotransferase-dependent conjugation) platforms, with Nona Biosciences’ Harbor Mice platform and  technologies, to further e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters